Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Immunome in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.63) per share for the quarter, up from their prior forecast of ($0.69). The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome's Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.40) EPS and FY2026 earnings at ($2.66) EPS.
Several other research firms have also commented on IMNM. Wedbush restated an "outperform" rating and set a $21.00 price target on shares of Immunome in a research report on Thursday. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. cut their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $23.14.
Read Our Latest Stock Analysis on IMNM
Immunome Stock Performance
Immunome stock opened at $9.69 on Monday. The company has a market capitalization of $843.42 million, a PE ratio of -3.15 and a beta of 1.93. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $16.73. The firm has a 50 day moving average price of $9.55 and a 200 day moving average price of $8.90.
Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The business had revenue of $4.02 million for the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%.
Insider Activity
In related news, Director Jean Jacques Bienaime bought 5,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average cost of $9.38 per share, with a total value of $46,900.00. Following the purchase, the director directly owned 36,415 shares of the company's stock, valued at $341,572.70. This trade represents a 15.92% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 7.69% of the company's stock.
Institutional Investors Weigh In On Immunome
A number of hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of Immunome during the fourth quarter worth about $70,000. Tower Research Capital LLC TRC lifted its stake in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after acquiring an additional 7,129 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Immunome in the fourth quarter worth approximately $95,000. ANTIPODES PARTNERS Ltd acquired a new position in Immunome during the 1st quarter worth approximately $95,000. Finally, Brighton Jones LLC acquired a new position in Immunome during the 2nd quarter worth approximately $98,000. Institutional investors and hedge funds own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.